Clinical applications of B-type natriuretic peptide (BNP) testing

European Heart Journal

Volumn 24, Issue 19, 2003, Pages 1710-1718

  Cowie, Martin R ^a   Jourdain, P ^b   Maisel, A ^c   Dahlstrom, U ^d   Follath, F ^e   Isnard, R ^f   Luchner, A ^g   McDonagh, T ^h   Mair, J ⁱ   Nieminen, M ^j   Francs, G ^k  

^a NATIONAL HEART AND LUNG INSTITUTE   (United Kingdom)

^b Heart Failure Department CHR   (France)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d LINKÖPING UNIVERSITY HOSPITAL   (Sweden)

^e UNIVERSITY HOSPITAL ZURICH   (Switzerland)

^f PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

^g Medizinische Klinik 1 Schwerpunkt Endokrinologie   (Germany)

^h UNIVERSITY OF GLASGOW   (United Kingdom)

ⁱ INNSBRUCK MEDICAL UNIVERSITY   (Austria)

^j HELSINKI UNIVERSITY CENTRAL HOSPITAL   (Finland)

^k LERNER RESEARCH INSTITUTE   (United States)

more..

Author keywords

B type natriuretic peptide; Diagnosis; Heart failure; Monitoring; Prognosis

Indexed keywords

BRAIN NATRIURETIC PEPTIDE;

AGE; CLINICAL PRACTICE; COMORBIDITY; DIAGNOSTIC IMAGING; DIAGNOSTIC VALUE; DYSPNEA; ECHOCARDIOGRAPHY; FIRST AID; GENDER; HEART FAILURE; HUMAN; NORMAL VALUE; OUTPATIENT; PATIENT MONITORING; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; REVIEW;

AMBULATORY CARE; EMERGENCY SERVICE, HOSPITAL; FLUORESCENT ANTIBODY TECHNIQUE; HEART FAILURE, CONGESTIVE; HUMANS; LABORATORY TECHNIQUES AND PROCEDURES; LUMINESCENT MEASUREMENTS; NATRIURETIC PEPTIDE, BRAIN; POINT-OF-CARE SYSTEMS; PROGNOSIS; SENSITIVITY AND SPECIFICITY; VENTRICULAR DYSFUNCTION, LEFT;

EID: 0141917517     PISSN: 0195668X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0195-668X(03)00476-7     Document Type: Review

References (68)

1. Nakao K, Ogawa Y, Suga S-I et al. Molecular biology and biochemistry of the natriuretic peptide system. I: natriuretic peptides. J Hypertension 1992;10:907-12.
2. Yasue H, Yoshimura M, Sumidan H et al. Localisation and mechanism of secretion of B-type natriuretic peptide in comparison with those of A-type natriuretic peptide in normal subjects and patients with heart failure. Circulation 1994;90:195-203.
3. Mukoyama M, Nakao K, Hosoda K et al. Brain natriuretic peptide as a novel cardiac hormone in humans: evidence for an exquisite dual natriuretic peptide system, atrial natriuretic peptide and brain natriuretic peptide. J Clin Invest 1991;87:1402-12.
4. Hosoda K, Nakao K, Mukoyama M et al. Expression of brain natriuretic peptide gene in human heart: production in the ventricle. Hypertension 1991;17:1152-6.
5. Nakao K, Mukoyama M, Hosoda K et al. Biosynthesis, secretion, and receptor selectivity of human brain natriuretic peptide. Can J Physiol Pharmacol 1991;69:1500-6.
6. Levin ER, Gardner DG, Samson WK. Natriuretic peptides. N Engl J Med 1998;339:321-8.
7. Holmes SJ, Espiner EA, Richards AM et al. Renal, endocrine, and hemodynamic effects of human brain natriuretic peptide in normal man. Clin Endocrinol Metab 1993;76:91-6.
8. Lang CC, Choy A-MJ, Struthers AD. Atrial and brain natriuretic peptides: a dual natriuretic peptide system potentially involved in circulatory homeostasis. Clin Sci 1992;83:519-27.
9. Yoshimura M, Yasue H, Morita E et al. Hemodynamic, renal, and hormonal responses to brain natriuretic peptide infusion in patients with congestive heart failure. Circulation 1991;84:1581-8.
10. McGregor A, Richards M, Espiner E et al. Brain natriuretic peptide administered to man: actions and metabolism. J Clin Endocrinol Metab 1990;70:1103-7.
11. La Villa G, Fronzaroli C, Lazzeri C et al. Cardiovascular and renal effects of low dose brain natriuretic peptide infusion in man. J Clin Endocrinol Metab 1994;78:1166-71.
12. Jensen KT, Carstens J, Pedersen EB. Effect of BNP on renal hemodynamics, tubular function and vasoactive hormones in humans. Am J Physiol 1998;274:F63-72.
13. Mukoyama M, Nakao K, Saito Y et al. Increased human brain natriuretic peptide in congestive heart failure. N Engl J Med 1990;323:757-8.
14. Groenning BA, Nilsson JC, Sondergaard L et al. Evaluation of impaired left ventricular ejection fraction and increased dimensions by multiple neurohumoral plasma concentrations. Eur J Heart Fail 2001;3:699-708.
15. Vogeser M, Jacob K. B-type natriuretic peptide (BNP) - validation of an immediate response assay. Clin Lab 2001;47:29-33.
16. Maisel AS, Koon J, Krishnaswamy P et al. Utility of B-natriuretic peptide as a rapid, point-of-care test for screening patients undergoing echocardiography to determine left ventricular dysfunction. Am Heart J 2001;141:367-74.
17. Hughes D, Talwar S, Squire IB et al. An immunoluminometric assay for N-terminal pro-brain natriuretic peptide: development of a test for left ventricular dysfunction. Clin Sci 1999;96:373-80.
18. Jensen KT, Carstens J, Ivarsen P et al. A new, fast and reliable radioimmunoassay of brain natriuretic peptide in human plasma. Reference values in healthy subjects and in patients with different diseases. Scand J Clin Lab Invest 1997;57:529-40.
19. Puschendorf B, Mair J. Cardiac diseases. In: Thomas L, editor. Clinical Laboratory Diagnostics-Use and Assessment of Clinical Laboratory Results. Frankfurt, Germany: TH Books; 1998, p. 101-19.
20. Wallen T, Landahl S, Hedner T et al. Brain natriuretic peptide in an elderly population. J Intern Med 1997;242:307-11.
21. Clerico A, Lervasi G, Mariani G. Pathophysiologic relevance of measuring the plasma levels of cardiac natriuretic peptide hormones in humans. Horm Metab Res 1999;31:487-98.
22. Richards AM, Nicholls MG, Yandle TG et al. Plasma N-terminal pro-brain natriuretic peptide and adrenomedullin: new neurohormonal predictors of left ventricular function and prognosis after myocardial infarction. Circulation 1998;97:1921-9.
23. Remes J, Miettinen H, Reunanen A et al. Validity of clinical diagnosis of heart failure in primary health care. Eur Heart J 1991;12:315-21.
24. Fox KF, Cowie MR, Wood DA et al. The aetiological importance of coronary artery disease in new cases of heart failure. Eur Heart J 2001;22:228-36.
25. Cowie MR, Struthers AD, Wood DA et al. Value of natriuretic peptides in assessment of patients with possible new heart failure in primary care. Lancet 1997;350:1349-53.
26. Wright SP, Doughty RN, Gamble GD et al. N-terminal BNP in the community diagnosis of suspected heart failure: what is an appropriate diagnostic threshold? Eur Heart J 2002;23(Suppl 4):271 (Abstract 1475. Presented at ESC, Berlin, August 2002).
27. Hobbs FD, Davis RC, Roalfe AK et al. Reliability of N-terminal pro-brain natriuretic peptide assay in diagnosis of heart failure: cohort study in representative and high risk community populations. BMJ 2002;324:1498-502.
28. Maisel AS, Krishnaswamy P, Nowak RM et al. Rapid measurement of B-type natriuretic peptide in the emergency diagnosis of heart failure. N Engl J Med 2002;347:161-7.
29. McCullough PA, Nowak RM, McCord J et al. B-type natriuretic peptide and clinical judgment in emergency diagnosis of heart failure: analysis from Breathing Not Properly (BNP) Multinational Study. Circulation 2002;106:416-22.
30. Maisel A. Algorithm for using b-type natriuretic peptide levels in the diagnosis and management of congestive heart failure. Critical Pathways in Cardiology 2000;1:68-73.
31. Luchner A, Burnett JC Jr., Jougasaki M et al. Augmentation of the cardiac natriuretic peptides by beta-receptor antagonism: evidence from a population-based study. J Am Coll Cardiol 1998;32:1839-44.
32. Yoshimura M, Yasue H, Tanaka H et al. Responses of plasma concentrations of A type natriuretic peptide and B type natriuretic peptide to alacepril, an angiotensin-converting enzyme inhibitor, in patients with congestive heart failure. Br Heart J 1994;72:528-33.
33. The Task Force for the Diagnosis and Treatment of Chronic Heart Failure, European Society of Cardiology. Guidelines for the diagnosis and treatment of chronic heart failure. Eur Heart J 2001;22:1527-60.
34. Uusimaa P, Ruskoaho H, Vuolteenaho O et al. Plasma vasoactive peptides after acute myocardial infarction in relation to left ventricular dysfunction. Int J Cardiol 1999;69:5-14.
35. Morita E, Yasue H, Yoshimura M et al. Increased plasma levels of brain natriuretic peptide in patients with acute myocardial infarction. Circulation 1993;88:82-91.
36. Horio T, Shimada K, Kohno M et al. Serial changes in atrial and brain natriuretic peptides in patients with acute myocardial infarction treated with early coronary angioplasty. Am Heart J 1993;126:293-9.
37. Choy A-MJ, Darbar D, Lang CC et al. Detection of left ventricular dysfunction after acute myocardial infarction: comparison of clinical, echocardiographic, and neurohormonal methods. Br Heart J 1994;72:16-22.
38. Omland T, Aakvaag A, Bonarjee VVS et al. Plasma brain natriuretic peptide as an indicator of left ventricular systolic dysfunction and long-term survival after acute myocardial infarction. Comparison with plasma atrial natriuretic peptide and N-terminal proatrial natriuretic peptide. Circulation 1996;93:1963-9.
39. McClure SJ, Caruana L, Davie AP et al. Cohort study of plasma natriuretic peptides for identifying left ventricular systolic dysfunction in primary care. BMJ 1998;317:516-9.
40. McDonagh T, Robb SD, Murdoch DR et al. Biochemical detection of left-ventricular systolic dysfunction. Lancet 1998;351:9-13.
41. Smith H, Pickering RM, Struthers AD et al. Biochemical diagnosis of ventricular dysfunction in elderly patients in general practice: observational study. BMJ 2000;320:906-8.
42. Hetmanski DJ, Sparrow NJ, Curtis S et al. Failure of plasma brain natriuretic peptide to identify left ventricular systolic dysfunction in the community. Heart 2000;84:440-1.
43. Luchner A, Burnett JC Jr., Jougasaki M et al. Evaluation of brain natriuretic peptide as marker of left ventricular dysfunction and hypertrophy in the population. J Hypertension 2000;18:1121-8.
44. Valli N, Georges A, Corcuff JB et al. Assessment of brain natriuretic peptide in patients with suspected heart failure: comparison with radionuclide ventriculography data. Clin Chim Acta 2001;306:19-26.
45. Kruger S, Graf J, Kunz D et al. brain natriuretic peptide levels predict functional capacity in patients with chronic heart failure. J Am Coll Cardiol 2002;40:718-22.
46. Koglin J, Pehlivanli S, Schwaiblmair M et al. Rate of brain natriuretic peptide in risk stratification of patients with congestive heart failure. J Am Coll Cardiol 2001;38:1934-41.
47. Tsutamoto T, Wada A, Maeda K et al. Attenuation of compensation of endogenous cardiac natriuretic peptide system in chronic heart failure: prognostic rate of plasma brain natriuretic peptide concentration in patients with chronic symptomatic left ventricular dysfunction. Circulation 1997;96:509-16.
48. Tsutamoto T, Wada A, Maeda K et al. Plasma brain natriuretic peptide level as a biochemical marker of morbidity and mortality in patients with asymptomatic or minimally symptomatic left ventricular dysfunction. Comparison with plasma angiotensin II and endothelin-1. Eur Heart J 1999;20:1799-807.
49. Yu CM, Sanderson JE. Plasma brain natriuretic peptide-an independent predictor of cardiovascular mortality in acute heart failure. Eur J Heart Fail 1999;1:59-65.
50. Cheng V, Kazanagra R, Garcia A et al. A rapid bedside test for B-type peptide predicts treatment outcomes in patients admitted for decompensated heart failure: a pilot study. J Am Coll Cardiol 2001;37:386-91.
51. Hulsmann M, Berger R, Sturm B et al. Prediction of outcome by neurohumoral activation, the six-minute walk test and the Minnesota Living with Heart Failure Questionnaire in an outpatient cohort with congestive heart failure. Eur Heart J 2002;23:886-91.
52. Stanek B, Frey B, Hulsmann M et al. Prognostic evaluation of neurohumoral plasma levels before and during beta-blocker therapy in advanced left ventricular dysfunction. J Am Coll Cardiol 2001;38:436-42.
53. Zugck C, Haunstetter A, Kruger C et al. Impact of beta-blocker treatment on the prognostic value of currently used risk predictors in congestive heart failure. J Am Coll Cardiol 2002;39:1615-22.
54. Gardner RS, Ozalp F, Murday AJ et al. N-Terminal brain natriuretic peptide: the new gold standard in predicting mortality in patients with advanced heart failure. J Am Coll Cardiol 2003;41(Supplement A):141A.
55. Berger R, Huelsman M, Strecker K et al. B-type natriuretic peptide predicts sudden death in patients with chronic heart failure. Circulation 2002;105:2392-7.
56. Richards AM, Crozier IG, Yandle TG et al. Brain natriuretic factor: regional plasma concentrations and correlations with haemodynamic state in cardiac disease. Br Heart J 1993;69:414-7.
57. Maisel A. Practical approaches to treating patients with acute decompensated heart failure. J Card Fail 2001;7(Suppl 1):13-7.
58. Lee SC, Stevens TL, Sandberg SM et al. The potential of brain natriuretic peptide as a biomarker for New York Heart Association class during the outpatient treatment of heart failure. J Card Fail 2002;8:149-54.
59. Murdoch DR, McDonagh TA, Byrne J et al. Titration of vasodilator therapy in chronic heart failure according to plasma brain natriuretic peptide concentration: randomized comparison of the hemodynamic and neuroendocrine effects of tailored versus empirical therapy. Am Heart J 1999;138:1126-32.
60. Cataliotti A, Malatino LS, Jougasaki M et at. Circulating natriuretic peptide concentrations in patients with end-stage renal disease: role of brain natriuretic peptide as a biomarker for ventricular remodeling. Mayo Clin Proc 2001;76:1111-9.
61. Troughton RW, Frampton CM, Yandle TG et al. Treatment of heart failure guided by plasma aminoterminal brain natriuretic peptide (N-BNP) concentrations. Lancet 2000;355:1126-30.
62. Richards AM, Doughty R, Nicholls MG et al. Neurohumoral prediction of benefit from carvedilol in ischemic left ventricular dysfunction. Australia-New Zealand Heart Failure Group. Circulation 1999;99:786-92.
63. Richards AM, Doughty R, Nicholls MG et al. Plasma N-terminal pro-brain natriuretic peptide and adrenomedullin: prognostic utility and prediction of benefit from carvedilol in chronic ischemic left ventricular dysfunction. Australia-New Zealand Heart FaiLure Group. J Am Coll Cardiol 2001;37:1781-7.
64. de Lemos JA, Morrow DA, Bentley JH et al. The prognostic value of B-type natriuretic peptide in patients with acute coronary syndromes. N Engl J Med 2001;345:1014-21.
65. Omland T, Persson A, Ng L et al. N-terminal pro-B-type natriuretic peptide and long-term mortality in acute coronary syndromes. Circulation 2002;106:2913-8.
66. Vasan RS, Benjamin EJ, Levy D. Prevalence, clinical features and prognosis of diastolic heart failure: an epidemiologic perspective. J Am Coll Cardiol 1995;26:1565-74.
67. Bonow R, Udelson JE. Left ventricular diastolic dysfunction as a cause of congestive heart failure. Ann Intern Med 1992;117:502-10.
68. Lubien E, DeMaria A, Krishnaswamy P et al. Utility of B-natriuretic peptide (BNP) in diagnosing diastolic dysfunction. Circulation 2002;105:595-601.